Litigation Details for Vectura Limited v. GlaxoSmithKline LLC (D. Del. 2016)

Vectura Limited v. GlaxoSmithKline LLC (D. Del. 2016)

Docket		Date Filed	2016-07-27
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Both	Referred To
Patents	8,303,991; 8,435,567; 8,956,661
Link to Docket	External link to docket

Details for Vectura Limited v. GlaxoSmithKline LLC (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-07-27	167		of multiple terms in U.S. Patent Nos. 8,303 ,991 ("the ' 991 patent") and 8,435,567 ("…construction for multiple terms in U.S. Patent Nos. 8,303,991 and 8,435,567. Within five days the parties… '661 patent, which shares a specification with the '991 patent. (' 661 patent, claim 1).… an unrelated Vectura patent, Patent No. 9,351 ,928 ("the ' 928 patent"). During prosecution…construction disputes for U.S. Patent No. 8,956,661 ("the ' 661 patent"). (D.I. 82 at 1 n.1)	External link to document
2016-07-27	272	Opinion - Memorandum Opinion	infringement of U.S. Patent Nos. 8,303 ,991 ("the '991 patent") and 8,435,567 ("the '…Plaintiffs patents and patent applications ("the Non-Assert Patents"), including the patents-in-suit…; 991 patent and claim 3 of the ' 567 patent ("the Asserted Claims"). The patents-in- suit…or sells any patented invention within the United States ... during the term of the patent therefor, infringes…infringes the patent." (emphasis added). As defined by § 271(a), the practice of a patented invention	External link to document
2016-07-27	276	Order - -Memorandum and Order	U.S . Patent No. 8,303 ,991 ("the 991 patent") and claim 3 of U.S . Patent No. 8,435,567 ("…#39;567 patent") (collectively, "the Asserted Claims"). (D.I. 1). The patents-in-suit …for inhalation, and in the case of the ' 567 patent, delays dissolution of the active material. (See… 27 July 2016 1:16-cv-00638-RGA Patent Both District Court, D. Delaware	External link to document
2016-07-27	3		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,303,991. (nmb) (Entered: 07… 27 July 2016 1:16-cv-00638-RGA Patent Both District Court, D. Delaware	External link to document
2016-07-27	6		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,435,567; . (Farnan, Kelly) … 27 July 2016 1:16-cv-00638-RGA Patent Both District Court, D. Delaware	External link to document

Vectura Limited v. GlaxoSmithKline LLC: Litigation Summary, Patent Scope, Damages, and Commercial Impact

Last updated: August 8, 2026

Vectura Limited v. GlaxoSmithKline LLC, No. 1:16-cv-00638-RGA, was a Delaware patent dispute concerning Vectura's dry-powder inhaler technology and GlaxoSmithKline's Ellipta inhaler platform. The principal patent was U.S. Patent No. 8,303,589, which covered structural and functional aspects of an inhaler using a blister strip to deliver pharmaceutical powder. A jury found infringement and awarded Vectura approximately $89.7 million. The case generated Federal Circuit appellate litigation addressing claim construction, infringement, validity, and the proper treatment of GSK's Ellipta inhalers. [1]

The dispute had commercial importance because Ellipta was used with several high-revenue respiratory medicines, including Breo Ellipta, Anoro Ellipta, Incruse Ellipta, and Trelegy Ellipta. The patent did not principally claim the active pharmaceutical ingredients. It targeted inhaler architecture and dose-delivery mechanics.

What patents were asserted in Vectura v. GSK?

The case centered on U.S. Patent No. 8,303,589, assigned to Vectura Limited. The patent is titled "Inhaler" and relates to dry-powder inhalers that use a strip carrying multiple dose-containing blisters.

U.S. Patent No. 8,303,589

Field	Information
Patent	U.S. Patent No. 8,303,589
Assignee	Vectura Limited
Technology	Dry-powder inhaler and blister-strip dose delivery
Filing history	Priority claimed to an early-2000s Vectura inhaler development program
Issue date	October 30, 2012
Asserted product family	GSK Ellipta inhalers
Court	U.S. District Court for the District of Delaware
District judge	Richard G. Andrews
Case number	1:16-cv-00638-RGA
Federal Circuit citation	981 F.3d 1030
Commercial relevance	Ellipta inhaler platform used across multiple respiratory products

The asserted claims addressed a dry-powder inhaler having, among other elements, a body, a mouthpiece, an air inlet, an air outlet, and a receptacle or blister arrangement for containing the powder formulation. The technical dispute focused on how those elements were arranged and how air passed through the inhaler during dose administration.

The patent was an inhaler-device patent rather than a conventional active-ingredient patent. Its value therefore depended on whether the claimed architecture was present in the commercial Ellipta device.

Which GSK products were accused of infringement?

Vectura accused GSK's Ellipta inhalers of infringing the '589 patent. The Ellipta platform is used with several inhaled medicines:

GSK product	Active ingredients	Primary indication	Ellipta platform relevance
Breo Ellipta	Fluticasone furoate/vilanterol	Asthma and COPD	Once-daily combination inhaler
Anoro Ellipta	Umeclidinium/vilanterol	COPD	Long-acting bronchodilator combination
Incruse Ellipta	Umeclidinium	COPD	Long-acting muscarinic antagonist
Trelegy Ellipta	Fluticasone furoate/umeclidinium/vilanterol	COPD and asthma	Single-inhaler triple therapy

GSK's position was that the Ellipta products did not meet the asserted claim limitations and that the patent claims were invalid. Vectura argued that the Ellipta inhalers incorporated the claimed blister-strip and airflow configuration.

The litigation did not turn primarily on whether GSK's drugs contained fluticasone furoate, vilanterol, umeclidinium, or another active ingredient. The central issue was whether the inhaler device satisfied the patent's structural limitations.

What was the procedural history of the Vectura-GSK patent case?

Vectura filed the Delaware action in 2016. The case proceeded through claim construction, fact and expert discovery, summary-judgment practice, and a jury trial.

Key procedural events

Date	Event
2016	Vectura filed the patent infringement complaint in Delaware
2017-2018	Claim construction and technical discovery concerning the '589 patent
2019	Jury trial and verdict for Vectura
2019	Jury awarded approximately $89.7 million in damages
2020	Federal Circuit issued its principal appellate decision
2020 onward	Further district-court proceedings followed the appellate ruling

The jury found the asserted claims infringed and rejected GSK's validity defenses. The damages award was based on a reasonable-royalty theory. Public reporting characterized the award as approximately $89.7 million, reflecting a royalty on relevant Ellipta sales during the damages period. [2]

The Federal Circuit decision, Vectura Limited v. GlaxoSmithKline LLC, 981 F.3d 1030 (Fed. Cir. 2020), addressed the district court's treatment of claim language and the relationship between the asserted claim limitations and the Ellipta inhalers. [1]

What did the Federal Circuit decide?

The Federal Circuit's decision focused on claim construction and infringement analysis for the '589 patent. The appellate court examined whether the district court had correctly interpreted terms concerning the inhaler's receptacle and airflow configuration.

The appellate record was significant for three reasons:

1. The case involved a device patent implemented across a product platform rather than a single drug.
2. The infringement analysis depended on detailed interpretation of inhaler architecture.
3. The appellate ruling affected whether the jury's infringement and damages findings could stand without further proceedings.

The Federal Circuit did not treat the presence of a blister strip, standing alone, as sufficient to establish infringement. The asserted claims required a particular combination of structural and functional elements. The court's analysis therefore had implications for future inhaler litigation in which the accused device uses a similar dose container but differs in airflow path, receptacle design, piercing mechanism, or mouthpiece arrangement.

The appellate ruling is commonly cited for the proposition that patent infringement analysis in inhaler cases must be tied closely to the complete claim combination. A competitor can avoid infringement even when it uses a similar dosage form or blister-based delivery concept if its device does not satisfy each construed limitation.

How much did GSK pay, and what was the damages theory?

The jury awarded Vectura approximately $89.7 million. The award was based on a royalty calculation rather than lost profits. The economic theory treated Vectura's patent as a technology license applicable to GSK's use of the claimed inhaler design.

Damages considerations

The damages analysis likely turned on:

• U.S. sales of accused Ellipta inhalers during the relevant period;
• The contribution of the inhaler technology to the overall product;
• Comparable licensing evidence;
• The commercial importance of the Ellipta platform;
• The scope and validity risk of the asserted patent;
• Whether the asserted technology was essential to the accused inhaler design.

A royalty applied to inhaler-platform sales can produce significant exposure because one device architecture may support several drug products. The resulting damages base can include sales associated with multiple active ingredients, even though the patent does not claim those ingredients directly.

The award was materially lower than a damages model based on total product profit or a substantial share of product revenue. That result is consistent with a device patent covering a component of a combination pharmaceutical product rather than the drug itself.

What was the Orange Book status of the Vectura patent?

The '589 patent was not an active-ingredient patent for fluticasone furoate, vilanterol, umeclidinium, or another Ellipta drug substance. Its principal subject matter was inhaler-device technology.

The FDA Orange Book generally lists patents submitted by an NDA holder that claim the approved drug, a method of using the drug, or certain drug-device combinations under applicable FDA listing standards. A device patent that does not claim the approved drug or an approved method of use is not automatically an Orange Book-listed patent.

The Vectura-GSK dispute was therefore different from a conventional Paragraph IV challenge involving a generic version of Advair, Breo, Anoro, Incruse, or Trelegy. The case was an infringement action against the originator's inhaler platform, not a generic drug applicant's certification dispute.

Regulatory implications

Issue	Vectura-GSK litigation
FDA pathway	NDA-based inhaled medicines
Patent type	Inhaler-device patent
Primary accused party	GSK
Typical generic mechanism	Paragraph IV certification
Central legal issue	Whether Ellipta devices practiced the asserted claims
Orange Book relevance	Limited compared with drug-substance or method-of-use patents

Did the case involve a Paragraph IV challenge?

No. The action was not initiated by a generic applicant under the Hatch-Waxman framework. Vectura, a patent owner, sued GSK for infringement in federal court.

A Paragraph IV case would ordinarily involve an abbreviated new drug application applicant asserting that a listed patent is invalid, unenforceable, or not infringed. Here, GSK was the branded product manufacturer and the accused infringer. The dispute did not present the ordinary generic-entry sequence of an ANDA filing, Paragraph IV notice, 30-month stay, and potential first-filer exclusivity.

The case nonetheless affected generic-entry analysis indirectly. If the patent had remained enforceable against the Ellipta platform, a future competitor using the same or substantially similar inhaler architecture could have faced infringement risk. A competitor using a different inhaler design would need to analyze the claims element by element.

When did the '589 patent lose exclusivity?

The '589 patent's enforceable term was tied to its earliest effective nonprovisional filing date, subject to patent-term adjustment and any applicable term extension. Because the patent originated from an early-2000s priority chain and issued in 2012, its ordinary U.S. patent term was expected to run into the mid-2020s, subject to the official USPTO term calculation.

The expiration date is commercially important because:

• A patent expiration eliminates ordinary infringement liability for post-expiration conduct;
• It does not erase liability for pre-expiration infringement;
• It does not invalidate separate patents covering the active ingredients, formulation, manufacturing process, or method of use;
• It does not necessarily remove regulatory exclusivity that arises independently under the FDCA.

Patent-term calculations should be taken from the USPTO patent record, including any patent-term adjustment and terminal disclaimer information. [3]

What formulation and method-of-use patents were relevant?

The '589 patent primarily protected inhaler construction and dose delivery. It did not broadly protect every formulation used in Ellipta products.

Separate patent categories can protect the commercial platform:

Formulation patents

Formulation patents may cover:

• Powder particle size;
• Carrier particles such as lactose;
• Micronized corticosteroids;
• Long-acting beta agonists;
• Long-acting muscarinic antagonists;
• Stabilizers and excipients;
• Specific drug combinations;
• Moisture-control characteristics.

Method-of-use patents

Method-of-use patents may cover:

• Once-daily administration;
• Treatment of COPD;
• Treatment of asthma;
• Specific dosing regimens;
• Patient populations;
• Triple-therapy or combination-therapy uses.

Manufacturing patents

Manufacturing patents may cover:

• Blister-strip production;
• Powder filling;
• Dose-metering operations;
• Sealing and foil-laminate structures;
• Device assembly;
• Quality-control processes;
• High-volume inhaler manufacture.

These rights can create a layered patent estate. The loss or invalidation of an inhaler patent does not necessarily remove protection for a drug formulation or approved use.

How strong was Vectura's patent position?

Vectura's position was strong enough to produce a jury verdict and an approximately $89.7 million damages award. The case also demonstrates the limits of platform-device patent protection.

Strengths

• The patent targeted a commercial device used across multiple products.
• The claimed technology related to the dose-delivery mechanism, not merely an optional formulation component.
• The accused products had substantial U.S. sales.
• Vectura secured a favorable jury finding on infringement and validity.
• The damages theory captured the economic value of platform use.

Weaknesses and litigation risks

• Inhaler claims are highly sensitive to claim construction.
• Minor differences in airflow, blister access, receptacle structure, or piercing mechanisms can determine infringement.
• A device patent can have limited leverage if a competitor redesigns the inhaler.
• Damages depend on apportionment between the inhaler, active ingredient, formulation, brand, and other product attributes.
• Patent expiration can arrive before regulatory or commercial barriers are fully removed.

The patent's practical strength was therefore greater against a direct copy of the Ellipta architecture than against a redesigned inhaler platform.

Which companies challenged the Ellipta platform?

The reported case involved Vectura as plaintiff and GSK as defendant. It was not a generic-versus-brand proceeding.

The broader competitive landscape included:

• Generic pharmaceutical companies developing inhaled corticosteroids and bronchodilators;
• Device manufacturers supplying dry-powder inhalers;
• Branded respiratory companies developing competing combination products;
• Companies pursuing authorized generics or alternative device presentations;
• Contract manufacturers with inhaler assembly and dose-filling capabilities.

A company seeking to compete with Ellipta products would need to assess at least four separate risk categories:

1. Drug-substance and formulation patents;
2. Method-of-use patents;
3. Inhaler-device patents;
4. Manufacturing and supply-chain know-how.

What generic launch risks existed for Ellipta products?

Generic launch risk depended on the product and patent layer.

A generic applicant could face:

• Orange Book-listed drug or method-of-use patents;
• FDA requirements for pharmaceutical equivalence and bioequivalence;
• Device-substitution and human-factors requirements;
• Infringement claims concerning inhaler architecture;
• Difficulty matching dose delivery and emitted-dose performance;
• Manufacturing constraints for blister strips and powder filling;
• Market-access barriers caused by device-specific patient training.

For a platform such as Ellipta, a generic product could avoid the '589 patent through a noninfringing inhaler design but still encounter separate formulation or method-of-use patents. Conversely, a formulation workaround would not resolve infringement risk if the substitute device practiced the asserted inhaler claims.

Did Vectura and GSK enter a settlement or license agreement?

The public record for the cited Delaware action establishes the patent litigation and appellate proceedings. The cited case materials do not establish a comprehensive settlement that can be treated as the operative resolution of all Vectura-GSK intellectual-property rights.

Vectura's broader business included inhaler technology licensing and collaborations with pharmaceutical companies. Its commercial model depended on licensing device and formulation technology to branded drug manufacturers. GSK's use of the Ellipta platform was therefore strategically important to Vectura's royalty and litigation position.

Vectura was acquired by Philip Morris International in 2021. That transaction shifted ownership of Vectura's respiratory intellectual-property assets but did not change the historical parties in the Delaware action. [4]

What was the commercial impact of the litigation?

The litigation created exposure across a portfolio of respiratory products rather than a single SKU. Ellipta's platform economics increased the value of the patent dispute because the same inhaler design supported multiple indications and combinations.

Potential commercial consequences included:

• Royalty exposure on U.S. Ellipta sales;
• Increased licensing leverage for Vectura;
• Design-around costs for future inhalers;
• Delays in competing product development;
• Greater diligence requirements for respiratory-product acquisitions;
• Valuation effects for companies owning inhaler patents or manufacturing capacity.

The dispute also illustrated a recurring pharmaceutical patent issue: a device patent can generate substantial litigation value even when it does not claim the active pharmaceutical ingredient. The commercial leverage comes from integration between the device, formulation, manufacturing process, regulatory approval, and patient-use instructions.

Key Takeaways

• Vectura sued GSK in Delaware over U.S. Patent No. 8,303,589.
• The patent covered dry-powder inhaler architecture involving blister-based dose delivery.
• The accused products were GSK's Ellipta inhalers, including Breo, Anoro, Incruse, and Trelegy.
• A jury found infringement and awarded approximately $89.7 million.
• The case was not a Paragraph IV generic challenge.
• The dispute centered on device infringement, not direct protection for fluticasone furoate, vilanterol, or umeclidinium.
• The Federal Circuit addressed claim-construction and infringement issues in 981 F.3d 1030.
• The '589 patent's commercial value came from coverage of a platform used across several respiratory products.
• Generic-entry analysis requires separate review of device, formulation, method-of-use, manufacturing, and Orange Book-listed rights.
• Patent expiration affects post-expiration infringement but does not eliminate liability for earlier conduct or separate patent barriers.

FAQs

What inhaler did Vectura accuse GSK of copying?

Vectura accused GSK's Ellipta inhalers of practicing claims of the '589 patent. The dispute concerned the inhaler's blister-strip and airflow architecture.

Did Vectura own the active-ingredient patents for Trelegy or Breo?

The cited litigation concerned inhaler-device technology. It did not establish that Vectura owned the active-ingredient patents for the drugs used in those products.

Could GSK avoid the Vectura patent by changing the inhaler?

Potentially. A redesigned inhaler that omitted at least one required claim element could avoid literal infringement, subject to the doctrine of equivalents and other patent claims.

Was the $89.7 million award based on lost profits?

The award was reported as a reasonable-royalty award, not a lost-profits award. The calculation related to GSK's use of the accused Ellipta inhaler technology.

Does expiration of the Vectura inhaler patent make Ellipta products generic?

No. Patent expiration does not create FDA approval, establish pharmaceutical equivalence, or remove separate formulation, method-of-use, manufacturing, or regulatory requirements.

References

1. United States Court of Appeals for the Federal Circuit. (2020). Vectura Limited v. GlaxoSmithKline LLC, 981 F.3d 1030.

2. United States District Court for the District of Delaware. (2019). Vectura Limited v. GlaxoSmithKline LLC, No. 1:16-cv-00638-RGA, jury-trial and post-trial docket materials.

3. United States Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent No. 8,303,589. https://patentcenter.uspto.gov/

4. Philip Morris International Inc. (2021). Philip Morris International completes acquisition of Vectura Group plc. Corporate transaction announcement.